Compare SRRK & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | TMDX |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.6B |
| IPO Year | 2018 | 2019 |
| Metric | SRRK | TMDX |
|---|---|---|
| Price | $42.47 | $110.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $55.40 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.3M | 927.9K |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | N/A | $24.12 |
| Revenue Next Year | $449.79 | $18.69 |
| P/E Ratio | ★ N/A | $23.31 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $22.71 | $62.42 |
| 52 Week High | $49.82 | $156.00 |
| Indicator | SRRK | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 30.85 |
| Support Level | $41.54 | $109.43 |
| Resistance Level | $42.54 | $131.86 |
| Average True Range (ATR) | 2.40 | 6.46 |
| MACD | 0.05 | -2.33 |
| Stochastic Oscillator | 38.83 | 3.41 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.